Evidence map›Paper›PMID 19798694›Full record

ReviewJournal of cellular physiology2010

GATA3 in development and cancer differentiation: cells GATA have it!

Jonathan Chou, Sylvain Provot, Zena Werb

Open access · greenAbstract readReview
In one paragraph

Review in Journal of cellular physiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed, 6 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

155 citing papers in PubMed, 6 syntheses or guidelines pooled it, 303 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: evidence from published data.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  5. The genetic association between pri-miR-34b/c polymorphism (rs4938723 T > C) and susceptibility to cancers: evidence from published studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  6. Pooled it
  7. Article
  8. The GATA3-RFPL3-ASK1 axis suppresses breast cancer growth and lung metastasis.Apoptosis : an international journal on programmed cell death · 2026
    Article
  9. High-Efficiency Genomic Mapping of Chromatin-Associated Targets with CUT&RUN.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

95 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jonathan ChouDepartment of Anatomy, University of California, San Francisco, California 94143-0452, USA.
Sylvain Provot
Zena Werb
University of California, San Francisco · US

Funding

Bay Area Breast Cancer &the Environment Research CenterU01ES012801 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HIATT, ROBERT A · 2003 to 2010
$12.4M
Role of Metalloproteinases in Mammary Gland RemodelingR01CA057621 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 1993 to 2017
$9.0M
TRANSCRIPTIONAL REGULATION OF BREAST CANCER METASTASISR01CA129523 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 2008 to 2012
$2.1M
NCI NIH HHS CA129523NCI NIH HHS R01 CA057621NCI NIH HHS R01 CA129523NIEHS NIH HHS ES012801NIEHS NIH HHS U01 ES012801
6 · The paper itself

Abstract

There is increasing evidence that the numerous mechanisms that regulate cell differentiation during normal development are also involved in tumorigenesis. In breast cancer, differentiation markers expressed by the primary tumor are routinely profiled to guide clinical decisions. Indeed, numerous studies have shown that the differentiation profile correlates with the metastatic potential of tumors. The transcription factor GATA3 has emerged recently as a strong predictor of clinical outcome in human luminal breast cancer. In the mammary gland, GATA3 is required for luminal epithelial cell differentiation and commitment, and its expression is progressively lost during luminal breast cancer progression as cancer cells acquire a stem cell-like phenotype. Importantly, expression of GATA3 in GATA3-negative, undifferentiated breast carcinoma cells is sufficient to induce tumor differentiation and inhibits tumor dissemination in a mouse model. These findings demonstrate the exquisite ability of a differentiation factor to affect malignant properties, and raise the possibility that GATA3 or its downstream genes could be used in treating luminal breast cancer. This review highlights our recent understanding of GATA3 in both normal mammary development and tumor differentiation.

Indexed as

Cell DifferentiationEmbryonic DevelopmentAnimalsBreast NeoplasmsFemaleGATA3 Transcription FactorHumansNeoplasm MetastasisOrgan SpecificityGATA3 Transcription Factor

Identifiers

PMID19798694
PMCPMC2915440
OpenAlexW2027944118

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.